Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMBODY trial: Empagliflozin versus placebo in acute myocardial infarction patients with type 2 diabetes mellitus
jRCTs031180185Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and myocardial infarction (MI) comparing Empagliflozin arm with Placebo arm (2 arms). Started Feb 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)myocardial infarction (MI)
Beyond the preview
Go deeper on jRCTs031180185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180185.